Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2013

View Archived Issues

Researchers report development of a novel murine model of ALS

Novartis identifies novel tankyrase inhibitor

Novel eicosapentaenoic acid derivative for the treatment of asthma

Cancer suicide gene therapy from INSERM shows promise in vivo

Trovagene's assay for detecting BRAF mutation in urine now available

Ventana launches automated test to detect BRAF V600E mutations

DiaMedica reports phase I/II DM-199 data in type 2 diabetes

DiaVacs commences phase Ib/IIa study of modified dendritic cells for type 1 diabetes

AIC-292 shows potent anti-HIV-1 activity in vivo and in first-in-human studies

Treatment with lanreotide leads to substantially prolonged PFS in patients with GEP-NET tumors

Two lupus organizations form collaboration to identify potential new treatments for the disease

Taiho Pharmaceutical patents new agents for cancer

Otsuka Pharmaceutical synthesizes novel monoamine reuptake inhibitors

New agents for influenza virus disclosed by Gilead Sciences

Astellas Pharma establishes new organization to oversee external alliance activities

Scientists at Purdue Pharma disclose new Na(v)1.7 channel blockers

DCPrime and Janssen collaborate to develop new dendritic cell-based vaccine

Axikin Pharmaceuticals divulges new MAP3K19 inhibitors

Trophos gives update on phase II TR-O40303 trial in myocardial infarction

CureVac and Janssen to collaborate on development of mRNA-based influenza vaccine

Orexigen Therapeutics submits MAA to EMA for Contrave

Jublia approved in Canada for the treatment of onychomycosis

X-Chem expands drug discovery collaboration with AstraZeneca

Addex Therapeutics reports preclinical data for ADX-71441 in Charcot-Marie-Tooth type 1A disease

First patient enrolled in phase II istaroxime study

Duavee approved for vasomotor symptoms and preventing postmenopausal osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...